DERM logo

Journey Medical Corporation Stock Price

NasdaqCM:DERM Community·US$140.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

DERM Share Price Performance

US$5.19
-1.84 (-26.17%)
US$13.25
Fair Value
US$5.19
-1.84 (-26.17%)
60.8% undervalued intrinsic discount
US$13.25
Fair Value
Price US$5.19
AnalystConsensusTarget US$13.25
AnalystHighTarget US$16.00
AnalystLowTarget US$11.00

DERM Community Narratives

·
Fair Value US$13.25 60.8% undervalued intrinsic discount

Rising Global Dermatologic Demand Will Fuel Future Success

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
·
Fair Value US$16 67.6% undervalued intrinsic discount

Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$11 52.8% undervalued intrinsic discount

Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$11
52.8% undervalued intrinsic discount
Profit Margin
26.15%
Future PE
8.32x
Price in 2029
US$13.47
US$16
67.6% undervalued intrinsic discount
Profit Margin
32.55%
Future PE
9.45x
Price in 2029
US$19.59

Trending Discussion

Updated Narratives

DERM logo

DERM: Expanded Access And Execution Progress Will Support Future Upside

Fair Value: US$13.25 60.8% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
DERM logo

Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement

Fair Value: US$11 52.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
DERM logo

Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside

Fair Value: US$16 67.6% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with high growth potential.

1 Risk
5 Rewards

Journey Medical Corporation Key Details

US$61.9m

Revenue

US$20.9m

Cost of Revenue

US$40.9m

Gross Profit

US$52.4m

Other Expenses

-US$11.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.42
66.17%
-18.48%
79.4%
View Full Analysis

About DERM

Founded
2014
Employees
58
CEO
Claude Maraoui
WebsiteView website
journeymedicalcorp.com

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.